Microba Life Sciences (ASX:MAP) agreed to transfer its non-core research services business to Denmark-headquartered microbiome genetic company Clinical Microbiomics, according to a Thursday filing with the Australian bourse.
The business registered AU$2.6 million in revenue in fiscal 2024 and operated on a cashflow breakeven basis.
Under the terms, the biotech company will retain its intellectual property and provide Clinical Microbiomics with certain transitional services for a fee.
Microba expects to receive up to AU$3 million in potential revenue over the next four years as a result of the transfer, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments